• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Fe3 Medical touts first transdermal anemia patch study

April 11, 2019 By Danielle Kirsh

fe3-medicalA Fe3 Medical study has shown that its Fe3 patch successfully delivers iron through the skin.

The study was designed to test the safety and tolerability of Fe3’s iontophoretic transdermal technology that bypasses ionic resistance build up in the skin. The human study comes after a series of successful preclinical studies that demonstrated the safe delivery of iron through skin.

Iron deficiency anemia is a condition that can result in fatigue, poor cognition and motor function defects. Oral iron is the only therapy option, according to the company, but more than 45% of patients are unable to tolerate the effects of oral therapy because of side effects.

The Fe3 iontophoretic transdermal patch along with a generic iron compound could offer an alternative therapeutic option for patients who can’t take oral iron. The patch delivers therapeutic levels of iron without gastrointestinal side effects. The patch has also shown to significantly reduce adverse effects of traditional transdermal drug delivery like burns and skin discoloration.

A Texas Clinical Research Organization in Texas conducted the study under Investigational Review Board approval. Safety and tolerability were studied in 40 healthy volunteers.

The Fe3 patch was applied to the thigh of a subject after mild skin preparation. The patch was programmed with short hydration inverts followed by five hours of active therapy. Results showed that there was successful iron transport with a rapid rise in serum iron levels in the first four hours and a declined return to baseline within 24 hours. Iron transport increases based on dosage were also monitored, as well as transport rates.

There were no reported adverse effects and no scarring or long-term staining of the skin. Mild edema and erythema were resolved within three days.

“We are focused on bringing a new therapy option to the millions of patients suffering from iron deficiency anemia on a worldwide basis,” Mark Sieczkarek, CEO of Fe3 Medical, said in a press release. “Our first human study, along with our extensive preclinical studies, give us the confidence that our transdermal patch technology can effectively and safely deliver therapeutic levels of iron. We are now preparing for the next exciting phase for Fe3 and an upcoming clinical trial.”

The Fe3 patch was developed at InCube Labs. The first in-human tests were performed after successfully preclinical tests in pigs.

“The transdermal technology platform that Fe3 is based on is capable of delivering a broad range of molecules in a highly controlled fashion, which makes it a great platform for iron, as well as other drugs such as Diclofenac for pain and inflammation and Sumatriptan for migraines,” Mir Imran, chairman and CEO of InCube Labs, said.

Filed Under: Drug-Device Combinations Tagged With: Fe3 Medical

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

About Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Design & Outsourcing, MassDevice, and Medical Tubing + Extrusion, and the founder of Women in Medtech and lead editor for Big 100. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at dkirsh@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS